Topic: ankylosing spondylitis
After underwhelming sales in the first quarter, Eli Lilly’s Taltz is on the hot seat with analysts. Long-term clear skin data could build its case.
Eli Lilly’s Taltz has followed Novartis rival Cosentyx into all its therapy areas. But this time, Lilly wants to be first.
With some new data in hand, Eli Lilly's Taltz looks poised to challenge Novartis' Cosentyx in a third indication.
In December, Eli Lilly’s Taltz got a go-ahead to take on rival Cosentyx from Novartis in its second indication. But it’s not stopping there.